Study: NCT05867251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVZO-021
Description: AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVZO-021
Description: AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVZO-021
Description: AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVZO-021
Description: AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Antineoplastic agent, cyclin-dependent kinase 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Antineoplastic agent, cyclin-dependent kinase 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Antineoplastic agent, estrogen receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Antineoplastic agent, estrogen receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Antineoplastic agent, aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Antineoplastic agent, aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Antineoplastic CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Antineoplastic CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Antineoplastic CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Antineoplastic CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Alkylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Alkylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Trop-2 antibody and topoisomerase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Trop-2 antibody and topoisomerase inhibitor